journal article·2014-10-28Open access

Brain-Penetrating Nanoparticles Improve Paclitaxel Efficacy in Malignant Glioma Following Local Administration

Elizabeth Nance, Clark Zhang, Ting-Yu Shih, Qingguo Xu, Benjamin S. Schuster, Justin Hanes

ACS Nano· Volume 8· Issue 10

Abstract

Poor drug distribution and short drug half-life within tumors strongly limit efficacy of chemotherapies in most cancers, including primary brain tumors. Local or targeted drug delivery via controlled-release polymers is a promising strategy to treat infiltrative brain tumors, which cannot be completely removed surgically. However, drug penetration is limited with conventional local therapies since small-molecule drugs often enter the first cell they encounter and travel only short distances from the site of administration. Nanoparticles that avoid adhesive interactions with the tumor extracellular matrix may improve drug distribution and sustain drug release when applied to the tumor area. We have previously shown model polystyrene nanoparticles up to 114 nm in diameter were able to rapidly diffuse in normal brain tissue, but only if coated with an exceptionally dense layer of poly(ethylene glycol) (PEG) to reduce adhesive interactions. Here, we demonstrate that paclitaxel (PTX)-loaded, poly(lactic-co-glycolic acid) (PLGA)-co-PEG block copolymer nanoparticles with an average diameter of 70 nm were able to diffuse 100-fold faster than similarly sized PTX-loaded PLGA particles (without PEG coatings). Densely PEGylated PTX-loaded nanoparticles significantly delayed tumor growth following local administration to established brain tumors, as compared to PTX-loaded PLGA nanoparticles or unencapsulated PTX. Delayed tumor growth combined with enhanced distribution of drug-loaded PLGA-PEG nanoparticles to the tumor infiltrative front demonstrates that particle penetration within the brain tumor parenchyma improves therapeutic efficacy. The use of drug-loaded brain-penetrating nanoparticles is a promising approach to achieve sustained and more uniform drug delivery to treat aggressive gliomas and potentially other brain disorders.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Glioma Diagnosis and Treatment · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center for Nanomedicine at the Wilmer Eye Institute, ‡Department of Biomedical Engineering, ∥Department of Ophthalmology, #Deparments of Oncology, Pharmacology and Molecular Sciences, and Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, United States

Department of Chemical & Biomolecular Engineering and ⊥Center for Cancer Nanotechnology Excellence, Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland 21218, United States

Funding

National Cancer Institute

References (55)

Show source-provided references
1. Wen P. Y. · N. Engl. J. Med. · 2008 · 359 · 49210.1056/NEJMra0708126 ↗
2. National Cancer Institute. · 2010
3. Preusser M. · Ann. Neurol. · 2011 · 70 · 910.1002/ana.22425 ↗
4. Gruber M. L. · J. Nucl. Med. · 1990 · 31 · 969
5. Stupp R. · N. Engl. J. Med. · 2005 · 352 · 98710.1056/NEJMoa043330 ↗
6. Wohlfart S. · J. Controlled Release · 2012 · 161 · 26410.1016/j.jconrel.2011.08.017 ↗
7. Patel T. · Adv. Drug Delivery Rev. · 2012 · 64 · 70110.1016/j.addr.2011.12.006 ↗
8. Fung L. K. · Pharm. Res. · 1996 · 13 · 67110.1023/A:1016083113123 ↗
9. Allard E. · Biomaterials · 2009 · 30 · 230210.1016/j.biomaterials.2009.01.003 ↗
10. Degen J. W. · J. Neurosurg. · 2003 · 99 · 89310.3171/jns.2003.99.5.0893 ↗
11. Lopez K. A. · Neurol. Res. · 2006 · 28 · 54210.1179/016164106X116836 ↗
12. Reulen H. J. · Acta Neurochir. Suppl. · 2010 · 106 · 310.1007/978-3-211-98811-4_1 ↗
13. Krauze M. T. · Neuro Oncol. · 2007 · 9 · 39310.1215/15228517-2007-019 ↗
14. Inoue T. · Neuro-Oncology · 2009 · 11 · 15110.1215/15228517-2008-068 ↗
15. Kreuter J. · Adv. Drug Delivery Rev. · 2001 · 47 · 6510.1016/S0169-409X(00)00122-8 ↗
16. Petri B. · J. Controlled Release · 2007 · 117 · 5110.1016/j.jconrel.2006.10.015 ↗
17. Steiniger S. C. · Int. J. Cancer · 2004 · 109 · 75910.1002/ijc.20048 ↗
18. Hekmatara T. · Clin. Neuropathol. · 2009 · 28 · 15310.5414/NPP28153 ↗
19. Nance E. A. · Sci. Transl. Med. · 2012 · 4 · 149ra11910.1126/scitranslmed.3003594 ↗
20. Gritsenko P. G. · J. Pathol. · 2012 · 226 · 18510.1002/path.3031 ↗
21. Pluen A. · Proc. Natl. Acad. Sci. U.S.A. · 2001 · 98 · 462810.1073/pnas.081626898 ↗
22. Sykova E. · Physiol. Rev. · 2008 · 88 · 127710.1152/physrev.00027.2007 ↗
23. Vargova L. · Glia · 2003 · 42 · 7710.1002/glia.10204 ↗
24. Zamecnik J. · Neuropathol. Appl. Neurobiol. · 2004 · 30 · 33810.1046/j.0305-1846.2003.00541.x ↗
25. Rosso L. · Cancer Res. · 2009 · 69 · 12010.1158/0008-5472.CAN-08-2356 ↗
26. Patel M. · J. Neurooncol. · 2003 · 61 · 20310.1023/A:1022592913323 ↗
27. Serwer L. P. · Adv. Drug Delivery Rev. · 2012 · 64 · 59010.1016/j.addr.2012.01.004 ↗
28. Baxter L. T. · Microvasc. Res. · 1989 · 37 · 7710.1016/0026-2862(89)90074-5 ↗
29. Baxter L. T. · Microvasc. Res. · 1990 · 40 · 24610.1016/0026-2862(90)90023-K ↗
30. Jain R. K. · Cancer Res. · 1988 · 48 · 7022
31. Boucher Y. · Cancer Res. · 1990 · 50 · 4478
32. Bhalla K. N. · Oncogene · 2003 · 22 · 907510.1038/sj.onc.1207233 ↗
33. Zhou J. · Proc. Natl. Acad. Sci. U.S.A. · 2013 · 110 · 1175110.1073/pnas.1304504110 ↗
34. Wohlfart S. · PLoS One · 2011 · 6 · e1912110.1371/journal.pone.0019121 ↗
35. Gelperina S. · Eur. J. Pharm. Biopharm. · 2010 · 74 · 15710.1016/j.ejpb.2009.09.003 ↗
36. Zensi A. · J. Drug Target · 2010 · 18 · 84210.3109/1061186X.2010.513712 ↗
37. Zensi A. · J. Controlled Release · 2009 · 137 · 7810.1016/j.jconrel.2009.03.002 ↗
38. Amoozgar Z. · Wiley Interdiscip Rev. Nanomed. Nanobiotechnol. · 2012 · 4 · 21910.1002/wnan.1157 ↗
39. Gref R. · Science · 1994 · 263 · 160010.1126/science.8128245 ↗
40. Maruyama K. · Adv. Drug Delivery Rev. · 2011 · 63 · 16110.1016/j.addr.2010.09.003 ↗
41. Claes A. · Acta Neuropathol. · 2007 · 114 · 44310.1007/s00401-007-0293-7 ↗
42. Treat L. H. · Ultrasound Med. Biol. · 2012 · 38 · 171610.1016/j.ultrasmedbio.2012.04.015 ↗
43. Yang F. Y. · IEEE Trans Ultrason. Ferroelectr. Freq. Control · 2011 · 58 · 96410.1109/TUFFC.2011.1897 ↗
44. Liu H. L. · Radiology · 2010 · 255 · 41510.1148/radiol.10090699 ↗
45. Nance, E. A.; Timbie, K.; Miller, G. W.; Song, J.; Louttit, C.; Klibanov, A. L.; Shih, T.S.; Swamination, G.; Tamargo, R. J.; Woodworth, G. F.; Hanes, J.; Price, R.Noninvasive Delivery of Stealth, Brain-Penetrating Nanoparticles across the Blood-Brain Barrier Using Mri-Guided Focused Ultrasound.J. Controlled Release 2014, in press10.1016/j.jconrel.2014.06.031 ↗
46. McDannold N. · Cancer Res. · 2012 · 72 · 365210.1158/0008-5472.CAN-12-0128 ↗
47. Kinoshita M. · Proc. Natl. Acad. Sci. U.S.A. · 2006 · 103 · 1171910.1073/pnas.0604318103 ↗
48. Jordao J. F. · PLoS One · 2010 · 5 · e1054910.1371/journal.pone.0010549 ↗
49. Yoo H. S. · Pharm. Res. · 1999 · 16 · 111410.1023/A:1018908421434 ↗
50. Xu Q. · J. Controlled Release · 2013 · 170 · 27910.1016/j.jconrel.2013.05.035 ↗
51. Lai S. K. · Proc. Natl. Acad. Sci. U.S.A. · 2007 · 104 · 148210.1073/pnas.0608611104 ↗
52. Crocker J. C. · J. Colloid Interface Sci. · 1996 · 179 · 29810.1006/jcis.1996.0217 ↗
53. Schuster B. S. · Mol. Ther. · 2014 · 22 · 148410.1038/mt.2014.89 ↗
54. Suh J. · Adv. Drug Delivery Rev. · 2005 · 57 · 6310.1016/j.addr.2004.06.001 ↗
55. Gullotti E. · J. Controlled Release · 2012 · 164 · 17010.1016/j.jconrel.2012.04.042 ↗